Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3899283 | 1.00 | F10 (0.56) | F10F2KLKB1 | |
| Hydrochloric Acid SCHEMBL3895982 | 0.99 | F10 (0.55) | F10F2KLKB1 | |
| Hydrochloric Acid SCHEMBL3895986 | 0.99 | F10 (0.55) | F10F2KLKB1 | |
| SCHEMBL3897884 | 0.90 | F10 (0.53) | F10F2KLKB1 | |
| SCHEMBL3897881 | 0.90 | F10 (0.53) | F10F2KLKB1 | |
| SCHEMBL13841664 | 0.90 | F10 (0.44) | F10F2KLKB1 | |
| SCHEMBL14641161 | 0.88 | F10 (0.43) | F10 | |
| SCHEMBL3909179 | 0.88 | F10 (0.58) | F10 | |
| SCHEMBL3897088 | 0.88 | F10 (0.47) | F10F2KLKB1 | |
| SCHEMBL3897092 | 0.88 | F10 (0.47) | F10F2KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534887-B2 | Thiazoline derivative and use of the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-19 | — | — | US | claimed |
| US-20070010528-A1 | Thiazoline derivative and use of the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | claimed |
| EP-1669352-A1 | THIAZOLINE DERIVATIVE AND USE OF THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2006-06-14 | — | — | EP | claimed |
| US-7534887-B2 | Thiazoline derivative and use of the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-19 | — | — | US | disclosed |
| US-20070010528-A1 | Thiazoline derivative and use of the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1669352-A1 | THIAZOLINE DERIVATIVE AND USE OF THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010528-A1 | Thiazoline derivative and use of the same | TBXA2R, F2, F3 | F10 90/4885F2 2/4885KLKB1 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.